M.X. Welliver

535 total citations
29 papers, 358 citations indexed

About

M.X. Welliver is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M.X. Welliver has authored 29 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M.X. Welliver's work include Sarcoma Diagnosis and Treatment (7 papers), Advanced Radiotherapy Techniques (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). M.X. Welliver is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Advanced Radiotherapy Techniques (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). M.X. Welliver collaborates with scholars based in United States, Israel and Japan. M.X. Welliver's co-authors include Mei Kong, Min Pan, Michael A. Reid, Yi Rong, Allison Quick, Arnab Chakravarti, Wenrui Duan, Gregory A. Otterson, Konstantin Shilo and Robert A. Baiocchi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular Cell.

In The Last Decade

M.X. Welliver

24 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.X. Welliver United States	8	154	113	109	88	57	29	358
Cihang Bao China	11	169 1.1×	118 1.0×	110 1.0×	112 1.3×	22 0.4×	19	398
Raffaele Piscitelli Italy	8	146 0.9×	74 0.7×	87 0.8×	149 1.7×	22 0.4×	18	336
Xinqiong Huang China	11	171 1.1×	143 1.3×	111 1.0×	45 0.5×	12 0.2×	18	347
Yenting Ngai United Kingdom	9	78 0.5×	90 0.8×	273 2.5×	381 4.3×	59 1.0×	17	557
József Lövey Hungary	12	90 0.6×	49 0.4×	168 1.5×	153 1.7×	62 1.1×	46	406
Tatsuji Mizukami Japan	9	235 1.5×	65 0.6×	104 1.0×	180 2.0×	51 0.9×	26	429
Yutaka Takezawa Japan	12	200 1.3×	63 0.6×	83 0.8×	191 2.2×	16 0.3×	43	467
Giuseppina Improta Italy	13	263 1.7×	80 0.7×	206 1.9×	122 1.4×	12 0.2×	31	468
Maria Hassan Pakistan	7	273 1.8×	68 0.6×	245 2.2×	57 0.6×	7 0.1×	19	479
Jana Halámková Czechia	10	191 1.2×	206 1.8×	191 1.8×	108 1.2×	6 0.1×	36	553

Countries citing papers authored by M.X. Welliver

Since Specialization

Citations

This map shows the geographic impact of M.X. Welliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.X. Welliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.X. Welliver more than expected).

Fields of papers citing papers by M.X. Welliver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.X. Welliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.X. Welliver. The network helps show where M.X. Welliver may publish in the future.

Co-authorship network of co-authors of M.X. Welliver

This figure shows the co-authorship network connecting the top 25 collaborators of M.X. Welliver. A scholar is included among the top collaborators of M.X. Welliver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.X. Welliver. M.X. Welliver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beaven, Anne, Susan M. Geyer, Jonathon B. Cohen, et al.. (2024). Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1661.3–1661.3.

Grilley‐Olson, Juneko E., Jacob B. Allred, Scott M. Schuetze, et al.. (2024). Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).. Journal of Clinical Oncology. 42(16_suppl). 11514–11514. 6 indexed citations

Welliver, M.X., et al.. (2023). A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation. International Journal of Surgical Pathology. 31(8). 1598–1604. 1 indexed citations

Konieczkowski, David J., Chengli Shen, Diamantis I. Tsilimigras, et al.. (2022). Prognostic factors in patients receiving surgery and radiation therapy for retroperitoneal sarcoma: A machine-learning analysis. Surgery. 173(3). 640–644. 4 indexed citations

Braggio, Danielle, Feng Jin, Abeba Zewdu, et al.. (2022). Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors. PLoS ONE. 17(10). e0276047–e0276047. 12 indexed citations

Cai, Shurui, Na Li, Xuetao Bai, et al.. (2022). ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. Theranostics. 12(16). 7051–7066. 23 indexed citations

Williams, Terence M., M.X. Welliver, Gregory A. Otterson, et al.. (2021). A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC). International Journal of Radiation Oncology*Biology*Physics. 111(3). S90–S90. 2 indexed citations

Patel, Sandipkumar, Lai Wei, Erin M. Bertino, et al.. (2021). P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation. Journal of Thoracic Oncology. 16(3). S363–S364.

Welliver, M.X., Brian Andrew Van Tine, Peter Houghton, et al.. (2019). MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).. Journal of Clinical Oncology. 37(15_suppl). TPS11076–TPS11076. 7 indexed citations

10.

Braggio, Danielle, Feng Jin, Abeba Zewdu, et al.. (2019). Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors. Cancer. 125(15). 2693–2703. 18 indexed citations

11.

Miller, Eric D., James L. Fisher, Kaisa Haglund, et al.. (2018). Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database. International Journal of Radiation Oncology*Biology*Physics. 102(3). e410–e410. 1 indexed citations

12.

Welliver, M.X., Sumithra Vasu, Naduparambil K. Jacob, et al.. (2018). Utilizing Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients with High-risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation: Results from a Prospective Pilot Study. International Journal of Radiation Oncology*Biology*Physics. 102(3). e370–e371. 5 indexed citations

13.

Bazan, Jose G., C. Barney, D.J. DiCostanzo, et al.. (2017). Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients Treated With Concurrent Chemoradiation for Locally Advanced Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 99(2). E440–E440.

14.

Mo, Xiaokui, C. Barney, J.C. Grecula, et al.. (2017). Tumor Volume Dynamics on kV-CBCT During Definitive Radiation Therapy for Locally Advanced NSCLC: Implications for Prognosis and Adaptive Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 99(2). E499–E500. 1 indexed citations

15.

Grecula, J.C., et al.. (2015). Mortality, Cardiac Toxicity, and Radiation Dose to the Heart in Patients Treated With Curative Intent Fractionated Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 93(3). S161–S161. 1 indexed citations

16.

Tyler, Kelly, Bradley M. Haverkos, Eileen Hu, et al.. (2015). The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Frontiers in Oncology. 5. 136–136. 24 indexed citations

17.

Williams, Terence M., et al.. (2015). Mortality, Cardiac Toxicity, and Radiation Dose to the Heart in Patients Treated With Curative Intent Fractionated Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 93(3). S177–S177. 3 indexed citations

18.

Rong, Yi, et al.. (2014). Improving Intra-Fractional Target Position Accuracy Using a 3D Surface Surrogate for Left Breast Irradiation Using the Respiratory-Gated Deep-Inspiration Breath-Hold Technique. PLoS ONE. 9(5). e97933–e97933. 48 indexed citations

19.

Reid, Michael A., et al.. (2013). The B55α Subunit of PP2A Drives a p53-Dependent Metabolic Adaptation to Glutamine Deprivation. Molecular Cell. 50(2). 200–211. 129 indexed citations

20.

Shilo, Konstantin, Xin Wu, M.X. Welliver, et al.. (2013). Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagnostic Pathology. 8(1). 201–201. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact